Ashley Flint, MPP

Articles by Ashley Flint, MPP

Reducing Out-of-Pocket Cost Barriers to Specialty Drug Use Under Medicare Part D: Addressing the Problem of "Too Much Too Soon"

ByJalpa A. Doshi, PhD,Pengxiang Li, PhD,Amy R. Pettit, PhD,J. Samantha Dougherty, PhD,Ashley Flint, MPP,Vrushabh P. Ladage, BS

March 17th 2017

Medicare claims analyses offer insight into how proposed policy changes would affect out-of-pocket prescription costs for Part D beneficiaries requiring specialty drugs.

Latest Updated Articles

Reducing Out-of-Pocket Cost Barriers to Specialty Drug Use Under Medicare Part D: Addressing the Problem of "Too Much Too Soon"
March 17th 2017

Ashley Flint, MPP

Articles by Ashley Flint, MPP

Reducing Out-of-Pocket Cost Barriers to Specialty Drug Use Under Medicare Part D: Addressing the Problem of "Too Much Too Soon"

Latest Updated Articles

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Ashley Flint, MPP

Articles by Ashley Flint, MPP

Reducing Out-of-Pocket Cost Barriers to Specialty Drug Use Under Medicare Part D: Addressing the Problem of "Too Much Too Soon"

Latest Updated Articles

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS